Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 11/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299051 | 0.89 | EPHX2 (0.44) | PYGLEPHX2KDM1AMAOBKMT2A | |
| SCHEMBL13299034 | 0.87 | EPHX2 (0.47) | PYGLEPHX2KDM1AMAOBKMT2A | |
| SCHEMBL13299015 | 0.87 | EPHX2 (0.47) | PYGLEPHX2KDM1AMAOBKMT2A | |
| SCHEMBL7329129 | 0.86 | KMT2A (0.46) | EPHX2KDM1AMAOBKMT2AL3MBTL1 | |
| SCHEMBL8652209 | 0.86 | KMT2A (0.46) | EPHX2KDM1AMAOBKMT2AL3MBTL1 | |
| SCHEMBL3332302 | 0.86 | EPHX2 (0.42) | PYGLEPHX2KDM1AMAOBKMT2A | |
| SCHEMBL7423742 | 0.83 | EPHX2 (0.48) | EPHX2KDM1AMAOBKMT2AL3MBTL1 | |
| SCHEMBL14016078 | 0.83 | EPHX2 (0.48) | EPHX2KDM1AMAOBKMT2AL3MBTL1 | |
| SCHEMBL4654164 | 0.83 | EPHX2 (0.48) | EPHX2KDM1AMAOBKMT2AL3MBTL1 | |
| SCHEMBL7335350 | 0.82 | PPARA (0.46) | EPHX2KDM1AMAOBKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137397-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | BIRCH ALAN MARTIN | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137397-A1 | Chemical Compounds | PYGL, PYGM, GYS2 | PYGL 1/4885EPHX2 2475/4885KDM1A 2935/4885 |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | PYGL, PYGM, GYS1 | PYGL 1/4885EPHX2 3678/4885KDM1A 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.